RFG Advisory, LLC
- SEC CIK
- 0001633387
- Latest filing
- Jul 15, 2026
The latest 13F from RFG Advisory, LLC covers Q2 2026 (filed Jul 15, 2026): 1,103 long positions worth $6.39B. The top 10 holdings make up 44.4% of the portfolio, and the largest is Exchange Traded Concepts Tru at 8.9%. Livermore has 22 filings on Form 13F from this institution, going back to Q1 2021.
What changed in Q2 2026
Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.
- New
- 142
- Est. +$126.4M
- Added
- 519
- Est. +$742.7M
- Reduced
- 413
- Est. −$378.6M
- Sold out
- 76
- Est. −$81.9M
Top 5 holdings
Share of this quarter's portfolio value
- Exchange Traded Concepts Tru3015053848.9%$566.7M
- Exchange Traded Concepts Tru3015053687.5%$479.5M
- Exchange Traded Concepts Tru3015053766.3%$404.6M
- Exchange Traded Concepts Tru3015054265.2%$332.0M
- Exchange Traded Concepts Tru3015053924.3%$274.1M
Biggest buys
New and added positions, by estimated amount bought
- Exchange Traded Concepts Tru301505376+$81.8MAdded
- Exchange Traded Concepts Tru301505384+$80.8MAdded
- Exchange Traded Concepts Tru301505368+$63.8MAdded
- Exchange Traded Concepts Tru301505426+$48.1MAdded
- Exchange Traded Concepts Tru301505418+$37.7MAdded
Largest weight increases
New and added positions, by percentage points of the portfolio gained
- Exchange Traded Concepts Tru301505384+1.23 pp7.6% → 8.9%
- Exchange Traded Concepts Tru301505376+1.10 pp5.2% → 6.3%
- Exchange Traded Concepts Tru301505426+0.70 pp4.5% → 5.2%
- Exchange Traded Concepts Tru301505418+0.63 pp3.6% → 4.3%
- Exchange Traded Concepts Tru301505392+0.38 pp3.9% → 4.3%
Biggest sells
Reduced and sold-out positions, by estimated amount sold
- BCRXBiocryst Pharmaceuticals Inc
- Invesco Exch Traded FD Tr II46138E222−$25.8MReduced
- Invesco Exch Traded FD Tr II46138E339−$18.3MReduced
- Invesco Nasdaq 100 ETF46138G649−$16.5MReduced
- Invesco S&P 500 Quality ETF46137V241−$8.38MReduced
Largest weight decreases
Reduced and sold-out positions, by percentage points of the portfolio lost
- BCRXBiocryst Pharmaceuticals Inc
- Invesco Exch Traded FD Tr II46138E222−0.44 pp0.6% → 0.1%
- Fidelity Merrimack STR Tr316188309−0.23 pp1.1% → 0.8%
- Invesco Nasdaq 100 ETF46138G649−0.22 pp0.5% → 0.3%
- Vanguard Total Bond Market ETF921937835−0.21 pp0.7% → 0.5%
Metrics
13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.
- Portfolio value
- $6.39B
- +$950.7M (+17.5%) vs. prior quarter
- Positions
- 1,103
- +66 vs. prior quarter
- Top 10 concentration
- 44.4%
- Top 10 as share of value
- Turnover
- 7.8%
- Q2 2026, one quarter
- Average holding period
- 10.4 quarters
- Weighted by value
How these are calculated
- Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
- Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
- Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
- Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.
13F filings by quarter
22 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.
Peak $6.39B (Q2 2026)
| Quarter | Filed | Positions | Value | Top 3 holdings | Changes | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Jul 15, 2026 | 1,103 | $6.39B | Exchange Traded Concepts TruExchange Traded Concepts TruExchange Traded Concepts Tru | vs. Q1 2026 | SEC |
| Q1 2026 | Apr 20, 2026 | 1,037 | $5.44B | Exchange Traded Concepts TruExchange Traded Concepts TruExchange Traded Concepts Tru | vs. Q4 2025 | SEC |
| Q4 2025 | Feb 3, 2026 | 979 | $5.31B | Exchange Traded Concepts TruExchange Traded Concepts TruExchange Traded Concepts Tru | vs. Q3 2025 | SEC |
| Q3 2025 | Nov 6, 2025 | 950 | $4.84B | Exchange Traded Concepts TruExchange Traded Concepts TruExchange Traded Concepts Tru | vs. Q2 2025 | SEC |
| Q2 2025 | Jul 28, 2025 | 920 | $4.26B | Exchange Traded Concepts TruExchange Traded Concepts TruExchange Traded Concepts Tru | vs. Q1 2025 | SEC |
| Q1 2025 | Apr 9, 2025 | 851 | $3.70B | Invesco Exchange Traded FD TState Street SPDR Portfolio S&P 500 Growth ETFVanguard Total Bond Market ETF | vs. Q4 2024 | SEC |
| Q4 2024 | Jan 21, 2025 | 758 | $3.54B | Invesco Exchange Traded FD TState Street SPDR Portfolio S&P 500 Growth ETFVanguard Total Bond Market ETF | vs. Q3 2024 | SEC |
| Q3 2024 | Oct 17, 2024 | 732 | $3.28B | Invesco Exchange Traded FD TState Street SPDR Portfolio S&P 500 Growth ETFVanguard Total Bond Market ETF | vs. Q2 2024 | SEC |
| Q2 2024 | Jul 15, 2024 | 699 | $3.07B | State Street SPDR Portfolio S&P 500 Growth ETFInvesco Exchange Traded FD TVanguard Total Bond Market ETF | vs. Q1 2024 | SEC |
| Q1 2024 | Apr 11, 2024 | 711 | $2.94B | Invesco Exchange Traded FD TState Street SPDR Portfolio S&P 500 Growth ETFVanguard Total Bond Market ETF | vs. Q4 2023 | SEC |
| Q4 2023 | Jan 25, 2024 | 645 | $2.57B | Invesco Exchange Traded FD TState Street SPDR Portfolio S&P 500 Growth ETFVanguard Total Bond Market ETF | vs. Q3 2023 | SEC |
| Q3 2023 | Oct 16, 2023 | 622 | $2.24B | Invesco Exchange Traded FD TState Street SPDR Portfolio S&P 500 Growth ETFVanguard Total Bond Market ETF | vs. Q2 2023 | SEC |
| Q2 2023 | Aug 3, 2023 | 631 | $2.25B | State Street SPDR Portfolio S&P 500 Growth ETFInvesco Exchange Traded FD TVanguard Total Bond Market ETF | vs. Q1 2023 | SEC |
| Q1 2023 | May 9, 2023 | 629 | $2.04B | State Street SPDR Portfolio S&P 500 Growth ETFInvesco Exchange Traded FD TVanguard Total Bond Market ETF | vs. Q4 2022 | SEC |
| Q4 2022 | Feb 15, 2023 | 612 | $1.98B | Invesco Exchange Traded FD TState Street SPDR Portfolio S&P 500 Growth ETFVanguard Total Bond Market ETF | vs. Q3 2022 | SEC |
| Q3 2022 | Nov 10, 2022 | 613 | $1.76B | Invesco Exchange Traded FD TState Street SPDR Portfolio S&P 500 Growth ETFState Street SPDR Portfolio Aggregate Bond ETF | vs. Q2 2022 | SEC |
| Q2 2022 | Aug 9, 2022 | 561 | $1.73B | Invesco Exchange Traded FD TState Street SPDR Portfolio S&P 500 Growth ETFState Street SPDR Portfolio Aggregate Bond ETF | vs. Q1 2022 | SEC |
| Q1 2022 | May 11, 2022 | 508 | $1.57B | Invesco Exchange Traded FD TState Street SPDR Portfolio Aggregate Bond ETFState Street SPDR Portfolio S&P 500 Growth ETF | vs. Q4 2021 | SEC |
| Q4 2021 | Feb 2, 2022 | 474 | $1.45B | State Street SPDR Portfolio S&P 500 Growth ETFInvesco Exchange Traded FD TState Street SPDR Portfolio Aggregate Bond ETF | vs. Q3 2021 | SEC |
| Q3 2021 | Oct 19, 2021 | 420 | $1.22B | State Street SPDR Portfolio Aggregate Bond ETFInvesco Exchange Traded FD TState Street SPDR Portfolio S&P 500 Growth ETF | vs. Q2 2021 | SEC |
| Q2 2021 | Jul 29, 2021 | 430 | $1.12B | Invesco Exchange Traded FD TState Street SPDR Portfolio Aggregate Bond ETFState Street SPDR Portfolio S&P 500 Growth ETF | vs. Q1 2021 | SEC |
| Q1 2021 | Apr 19, 2021 | 431 | $917.8M | Invesco Exchange Traded FD TState Street SPDR Portfolio Aggregate Bond ETFState Street SPDR Portfolio S&P 500 Growth ETF | – | SEC |